FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2958440246> ?p ?o ?g. }

• W2958440246 endingPage "1278" @default.
• W2958440246 startingPage "1270" @default.
• W2958440246 abstract "Abstract Drugs that inhibit the sodium–glucose co‐transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new‐onset heart failure events by ≈30%. In addition, in the EMPA‐REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as diuretics or anti‐hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes. The EMPEROR‐Reduced trial is enrolling ≈3600 patients with heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin–angiotensin system and neprilysin, beta‐blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time‐to‐first event analysis of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all‐cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic peptide levels to the baseline ejection fraction, the trial will preferentially enrol high‐risk patients. A large proportion of the participants is expected to have an ejection fraction < 30%, and the estimated annual event rate is expected to be at least 15%. The EMPEROR‐Reduced trial is well‐positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction." @default.
• W2958440246 created "2019-07-23" @default.
• W2958440246 creator A5018407061 @default.
• W2958440246 creator A5078418468 @default.
• W2958440246 date "2019-07-16" @default.
• W2958440246 modified "2023-10-14" @default.
• W2958440246 title "Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial" @default.
• W2958440246 cites W1990025047 @default.
• W2958440246 cites W1997249895 @default.
• W2958440246 cites W2042027582 @default.
• W2958440246 cites W2046125339 @default.
• W2958440246 cites W2056680550 @default.
• W2958440246 cites W2146264128 @default.
• W2958440246 cites W2273304042 @default.
• W2958440246 cites W2412800896 @default.
• W2958440246 cites W2416348735 @default.
• W2958440246 cites W2424539745 @default.
• W2958440246 cites W2538443876 @default.
• W2958440246 cites W2584401577 @default.
• W2958440246 cites W2626446274 @default.
• W2958440246 cites W2741979119 @default.
• W2958440246 cites W2743981289 @default.
• W2958440246 cites W2745294544 @default.
• W2958440246 cites W2746903407 @default.
• W2958440246 cites W2756132236 @default.
• W2958440246 cites W2760952310 @default.
• W2958440246 cites W2763866789 @default.
• W2958440246 cites W2765278092 @default.
• W2958440246 cites W2772835527 @default.
• W2958440246 cites W2797845698 @default.
• W2958440246 cites W2884144220 @default.
• W2958440246 cites W2888544493 @default.
• W2958440246 cites W2889590224 @default.
• W2958440246 cites W2898779626 @default.
• W2958440246 cites W2900413769 @default.
• W2958440246 cites W2921866736 @default.
• W2958440246 cites W2923389432 @default.
• W2958440246 cites W2936593438 @default.
• W2958440246 cites W2939222610 @default.
• W2958440246 cites W2943788550 @default.
• W2958440246 cites W2944562662 @default.
• W2958440246 cites W2964930911 @default.
• W2958440246 cites W2965056983 @default.
• W2958440246 doi "https://doi.org/10.1002/ejhf.1536" @default.
• W2958440246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31584231" @default.
• W2958440246 hasPublicationYear "2019" @default.
• W2958440246 type Work @default.
• W2958440246 sameAs 2958440246 @default.
• W2958440246 citedByCount "155" @default.
• W2958440246 countsByYear W29584402462020 @default.
• W2958440246 countsByYear W29584402462021 @default.
• W2958440246 countsByYear W29584402462022 @default.
• W2958440246 countsByYear W29584402462023 @default.
• W2958440246 crossrefType "journal-article" @default.
• W2958440246 hasAuthorship W2958440246A5018407061 @default.
• W2958440246 hasAuthorship W2958440246A5078418468 @default.
• W2958440246 hasBestOaLocation W29584402461 @default.
• W2958440246 hasConcept C126322002 @default.
• W2958440246 hasConcept C134018914 @default.
• W2958440246 hasConcept C164705383 @default.
• W2958440246 hasConcept C168563851 @default.
• W2958440246 hasConcept C203092338 @default.
• W2958440246 hasConcept C2775887513 @default.
• W2958440246 hasConcept C2777180221 @default.
• W2958440246 hasConcept C2777422806 @default.
• W2958440246 hasConcept C2777451236 @default.
• W2958440246 hasConcept C2778198053 @default.
• W2958440246 hasConcept C2993353509 @default.
• W2958440246 hasConcept C555293320 @default.
• W2958440246 hasConcept C71924100 @default.
• W2958440246 hasConcept C78085059 @default.
• W2958440246 hasConceptScore W2958440246C126322002 @default.
• W2958440246 hasConceptScore W2958440246C134018914 @default.
• W2958440246 hasConceptScore W2958440246C164705383 @default.
• W2958440246 hasConceptScore W2958440246C168563851 @default.
• W2958440246 hasConceptScore W2958440246C203092338 @default.
• W2958440246 hasConceptScore W2958440246C2775887513 @default.
• W2958440246 hasConceptScore W2958440246C2777180221 @default.
• W2958440246 hasConceptScore W2958440246C2777422806 @default.
• W2958440246 hasConceptScore W2958440246C2777451236 @default.
• W2958440246 hasConceptScore W2958440246C2778198053 @default.
• W2958440246 hasConceptScore W2958440246C2993353509 @default.
• W2958440246 hasConceptScore W2958440246C555293320 @default.
• W2958440246 hasConceptScore W2958440246C71924100 @default.
• W2958440246 hasConceptScore W2958440246C78085059 @default.
• W2958440246 hasIssue "10" @default.
• W2958440246 hasLocation W29584402461 @default.
• W2958440246 hasLocation W29584402462 @default.
• W2958440246 hasLocation W29584402463 @default.
• W2958440246 hasLocation W29584402464 @default.
• W2958440246 hasLocation W29584402465 @default.
• W2958440246 hasLocation W29584402466 @default.
• W2958440246 hasLocation W29584402467 @default.
• W2958440246 hasOpenAccess W2958440246 @default.
• W2958440246 hasPrimaryLocation W29584402461 @default.
• W2958440246 hasRelatedWork W2118342742 @default.
• W2958440246 hasRelatedWork W2192206197 @default.
• W2958440246 hasRelatedWork W2600856845 @default.

• next